Summit Investment Advisors Inc. Raises Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Summit Investment Advisors Inc. boosted its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 3.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 23,560 shares of the biotechnology company’s stock after purchasing an additional 746 shares during the quarter. Summit Investment Advisors Inc.’s holdings in ADMA Biologics were worth $404,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC increased its holdings in shares of ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 967 shares during the period. Mark Sheptoff Financial Planning LLC purchased a new position in ADMA Biologics during the fourth quarter worth about $35,000. Vision Financial Markets LLC purchased a new stake in shares of ADMA Biologics in the 4th quarter valued at about $51,000. AlphaQuest LLC purchased a new stake in shares of ADMA Biologics in the 4th quarter valued at about $84,000. Finally, CIBC Private Wealth Group LLC boosted its position in shares of ADMA Biologics by 137.1% during the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company’s stock valued at $95,000 after acquiring an additional 2,954 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Trading Up 0.4 %

Shares of ADMA stock opened at $21.31 on Friday. The business has a 50-day moving average price of $18.26 and a two-hundred day moving average price of $18.22. ADMA Biologics, Inc. has a 12-month low of $6.19 and a 12-month high of $23.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The firm has a market cap of $5.04 billion, a P/E ratio of 76.11 and a beta of 0.53.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.